Skip to main content
SpringerLink
Log in

Long-term effectiveness of zoledronic acid in patients with Paget’s disease of bone – a retrospective cohort study

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

The aims of the current study were to describe clinical and biochemical features of patients with Paget disease of bone (PDB) followed at our medical center, and to examine the long-term effectiveness of zoledronate.

Methods

Retrospective cohort study included consecutive patients≥18 years with a diagnosis of PDB, followed in the Rabin Medical Center (RMC) Institute of Endocrinology from 1973 to 2023. The cohort comprised two groups: patients treated/not treated with zoledronic acid (ZOL/NZOL). The primary outcome was the percentage of patients who achieved a biochemical therapeutic response.

Results

Overall, 101 patients with PDB were included, 68 in the ZOL group and 33 in the NZOL group. The mean age was 65.2 ± 10.0 years, and 47% were female. Notably, 77% exhibited monostotic involvement, and only 3% had experienced fractures attributed to PDB. Mean ALP level at diagnosis was 160 ± 70.6 U/L. The median follow-up duration was 17 years since PDB diagnosis, comparable between the groups. Primary outcome was more prevalent in the ZOL compared to the NZOL group [42 patients (88%) VS 11 patients (52%) respectively, P = 0.004]. At the end of follow-up, mean ALP levels in the NZOL group were significantly higher than the levels in the ZOL group irrespective of the number of infusions received.

Conclusion

The majority of patients with PDB experience a mild disease course, marked by monostotic involvement and a low prevalence of fractures. Zoledronic acid effectively manages PDB, providing sustained biochemical response. The necessity for multiple zoledronic acid injections remains questionable, often implemented due to osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. M. Davie, M. Davies, R. Francis, W. Fraser, D. Hosking, R. Tansley, Paget’s disease of bone: a review of 889 patients. Bone 24(5), 11S–12S (1999). https://doi.org/10.1016/S8756-3282(99)00027-7

    Article  CAS  PubMed  Google Scholar 

  2. R.D. Altman, D.A. Bloch, M.C. Hochberg, W.A. Murphy, Prevalence of pelvic Paget’s disease of bone in the United States. J. Bone Min. Res 15(3), 461–465 (2010). https://doi.org/10.1359/jbmr.2000.15.3.461

    Article  Google Scholar 

  3. C. Cooper, K. Schafheutle, E. Dennison, S. Kellingray, P. Guyer, D. Barker, The epidemiology of Paget’s disease in Britain: is the prevalence decreasing? J. Bone Min. Res 14(2), 192–197 (1999). https://doi.org/10.1359/jbmr.1999.14.2.192

    Article  CAS  Google Scholar 

  4. E. Gendron, F. Bouchard, N. Singbo, J.P. Brown, L. Michou, Decline in clinical severity of Paget’s disease of bone: comparison between a contemporary cohort and a historical cohort. Bone 170, 116721 (2023). https://doi.org/10.1016/j.bone.2023.116721

    Article  PubMed  Google Scholar 

  5. A.A. Morales-Piga, F.J. Bachiller-Corral, V. Abraira, J. Beltrán, A. Rapado, Is clinical expressiveness of Paget’s disease of bone decreasing? Bone 30(2), 399–403 (2002). https://doi.org/10.1016/S8756-3282(01)00674-3

    Article  CAS  PubMed  Google Scholar 

  6. C. Britton, S. Brown, L. Ward, S.L. Rea, T. Ratajczak, J.P. Walsh, The changing presentation of Paget’s disease of bone in Australia, a high prevalence region. Calcif. Tissue Int 101(6), 564–569 (2017). https://doi.org/10.1007/s00223-017-0312-1

    Article  CAS  PubMed  Google Scholar 

  7. R.D. Tiegs, C.M. Lohse, P.C. Wollan, L.J. Melton, Long-term trends in the incidence of Paget’s disease of bone. Bone 27(3), 423–427 (2000). https://doi.org/10.1016/S8756-3282(00)00333-1

    Article  CAS  PubMed  Google Scholar 

  8. S.H. Ralston, L. Corral-Gudino, C. Cooper, R.M. Francis, W.D. Fraser, L. Gennari, N. Guañabens, M.K. Javaid, R. Layfield, T.W. O’Neill, R.G.G. Russell, M.D. Stone, K. Simpson, D. Wilkinson, R. Wills, M.C. Zillikens, S.P. Tuck, Diagnosis and management of Paget’s disease of bone in adults: a clinical guideline: diagnosis and management of Paget’s disease of bone. J. Bone Min. Res 34(4), e3657 (2019). https://doi.org/10.1002/jbmr.3657

    Article  Google Scholar 

  9. F.R. Singer, H.G. Bone, D.J. Hosking, K.W. Lyles, M.H. Murad, I.R. Reid, E.S. Siris; Endocrine Society, Paget’s disease of bone: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(12), 4408–4422 (2014). https://doi.org/10.1210/jc.2014-2910

    Article  CAS  PubMed  Google Scholar 

  10. J.P. Lavender, I.M.A. Evans, R. Arnot, S. Bowring, F.H. Doyle, G.F. Joplin, I. MacIntyre, A comparison of radiography and radioisotope scanning in the detection of Paget’s disease and in the assessment of response to human calcitonin. BJR 50(592), 243–250 (1977). https://doi.org/10.1259/0007-1285-50-592-243

    Article  CAS  PubMed  Google Scholar 

  11. I.R. Reid, G.C. Nicholson, R.S. Weinstein, D.J. Hosking, T. Cundy, M.A. Kotowicz, W.A. Murphy, S. Yeap, S. Dufresne, A. Lombardi, T.A. Musliner, D.E. Thompson, A. John Yates, Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am. J. Med. 101(4), 341–348 (1996). https://doi.org/10.1016/S0002-9343(96)00227-6

    Article  CAS  PubMed  Google Scholar 

  12. P.D. Miller, J.P. Brown, E.S. Siris, M.S. Hoseyni, D.W. Axelrod, P.J. Bekker, A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am. J. Med. 106(5), 513–520 (1999). https://doi.org/10.1016/S0002-9343(99)00062-5

    Article  CAS  PubMed  Google Scholar 

  13. J.P. Walsh, L.C. Ward, G.O. Stewart, R.K. Will, R.A. Criddle, R.L. Prince, B.G.A. Stuckey, S.S. Dhaliwal, C.I. Bhagat, R.W. Retallack, G.N. Kent, P.J. Drury, S. Vasikaran, D.H. Gutteridge, A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone 34(4), 747–754 (2004). https://doi.org/10.1016/j.bone.2003.12.011

    Article  CAS  PubMed  Google Scholar 

  14. I.R. Reid, P. Miller, K. Lyles, W. Fraser, J.P. Brown, Y. Saidi, P. Mesenbrink, G. Su, J. Pak, K. Zelenakas, M. Luchi, P. Richardson, D. Hosking, Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med 353(9), 898–908 (2005). https://doi.org/10.1056/NEJMoa044241

    Article  CAS  PubMed  Google Scholar 

  15. I.R. Reid, K. Lyles, G. Su, J.P. Brown, J.P. Walsh, J. del Pino-Montes, P.D. Miller, W.D. Fraser, S. Cafoncelli, C. Bucci-Rechtweg, D.J. Hosking, A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J. Bone Min. Res 26(9), 2261–2270 (2011). https://doi.org/10.1002/jbmr.438

    Article  CAS  Google Scholar 

  16. D. Merlotti, L. Gennari, G. Martini, F. Valleggi, V. De Paola, A. Avanzati, R. Nuti, Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J. Bone Min. Res 22(10), 1510–1517 (2007). https://doi.org/10.1359/jbmr.070704

    Article  CAS  Google Scholar 

  17. D. Hosking, K. Lyles, J.P. Brown, W.D. Fraser, P. Miller, M.D. Curiel, J.-P. Devogelaer, M. Hooper, G. Su, K. Zelenakas, J. Pak, T. Fashola, Y. Saidi, E.F. Eriksen, I.R. Reid, Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J. Bone Min. Res 22(1), 142–148 (2007). https://doi.org/10.1359/jbmr.061001

    Article  CAS  Google Scholar 

  18. A. Tan, S.H. Ralston, Clinical presentation of Paget’s disease: evaluation of a contemporary cohort and systematic review. Calcif. Tissue Int 95(5), 385–392 (2014). https://doi.org/10.1007/s00223-014-9904-1

    Article  CAS  PubMed  Google Scholar 

  19. M. Barale, S. Sigrist, F. Bioletto, F. Maiorino, E. Ghigo, R. Mazzetti, M. Procopio, Long-term efficacy of intensive zoledronate therapy and predictors of retreatment in Paget’s disease of bone. Calcif. Tissue Int 109(4), 383–392 (2021). https://doi.org/10.1007/s00223-021-00848-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. A.L. Langston, M.K. Campbell, W.D. Fraser, G.S. MacLennan, P.L. Selby, S.H. Ralston, Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J. Bone Min. Res 25(1), 20–31 (2010). https://doi.org/10.1359/jbmr.090709

    Article  CAS  Google Scholar 

  21. A. Tan, K. Goodman, A. Walker, J. Hudson, G.S. MacLennan, P.L. Selby, W.D. Fraser, S.H. Ralston; for the PRISM-EZ Trial Group, Long-term randomized trial of intensive versus symptomatic management in Paget’s disease of bone: the PRISM-EZ study: intensive bisphosphonate therapy in Paget’s disease of bone. J. Bone Min. Res 32(6), 1165–1173 (2017). https://doi.org/10.1002/jbmr.3066

    Article  CAS  Google Scholar 

  22. T. Cundy, K. Maslowski, A. Grey, I.R. Reid, Durability of response to zoledronate treatment and competing mortality in Paget’s disease of bone. J. Bone Min. Res 32(4), 753–756 (2017). https://doi.org/10.1002/jbmr.3029

    Article  CAS  Google Scholar 

  23. I.R. Reid, J.P. Brown, N. Levitt, J.A. Román Ivorra, J. Bachiller-Corral, I.L. Ross, G. Su, O. Antunez-Flores, R.P. Aftring, Re-treatment of relapsed Paget’s disease of bone with zoledronic acid: results from an open-label study. Bonekey Rep. 2, 442 (2013). https://doi.org/10.1038/bonekey.2013.176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funds, grants, or other support was received.

Author information

Authors and Affiliations

  1. Institute of Endocrinology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel

    Irit Ayalon-Dangur, Yaron Rudman, Gloria Tsvetov, Ilana Slutzky-Shraga, Amit Akirov, Ilan Shimon, Dania Hirsch & Alexander Gorshtein

  2. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Irit Ayalon-Dangur, Yaron Rudman, Gloria Tsvetov, Ilana Slutzky-Shraga, Amit Akirov, Ilan Shimon, Dania Hirsch & Alexander Gorshtein

Authors
  1. Irit Ayalon-Dangur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaron Rudman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gloria Tsvetov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilana Slutzky-Shraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amit Akirov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ilan Shimon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dania Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alexander Gorshtein
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study Conception and design: Gorshtein A, Ayalon-Dangur I.Acquisition of data: All authors.Analysis and interpretation of data: Gorshtein A, Ayalon-Dangur I, Rudman Y.Drafting of the work: Gorshtein A, Ayalon-Dangur I.Critical Revision of the manuscript: All authors.Study supervision: Gorshtein A.Final approval of the manuscript: All authors.

Corresponding author

Correspondence to Alexander Gorshtein.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayalon-Dangur, I., Rudman, Y., Tsvetov, G. et al. Long-term effectiveness of zoledronic acid in patients with Paget’s disease of bone – a retrospective cohort study. Endocrine (2024). https://doi.org/10.1007/s12020-024-03791-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12020-024-03791-7

Keywords

Search

Navigation